A Targeted Therapy for Psoriasis, Psoriatic Arthritis, and Crohn’s Disease

SKYRIZI^® is a targeted biologic treatment specifically approved for adults with moderately to severely active Crohn’s disease, adults with moderately to severely active ulcerative colitis, adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy, and adults with active psoriatic arthritis. As part of VIP Rheumatology’s comprehensive care approach, SKYRIZI^® provides an FDA-approved treatment that works by selectively blocking interleukin-23 (IL-23), a key protein involved in the inflammatory process that contributes to psoriasis and psoriatic arthritis.

With SKYRIZI^®, many patients experience significant benefits:

• Induce remission in patients with moderately to severely active Crohn’s disease and ulcerative colitis
• Dramatic skin clearance with many achieving completely clear or almost clear skin
• Long-lasting relief from psoriatic plaques and associated symptoms
• Improvement in joint pain, swelling, and stiffness for psoriatic arthritis patients
• Convenient maintenance dosing schedule of just once every 12 weeks after initial doses

One remarkable feature of SKYRIZI^® is its unique ability to provide powerful, long-lasting results with minimal maintenance doses. By targeting a specific pathway in the immune system, SKYRIZI^® offers a more targeted approach to treating psoriatic disease. Many patients experience noticeable improvements in skin symptoms within just 16 weeks of starting treatment, with results continuing to improve and maintain over time.